Tecan and innovatis Collaborate to Enhance the Automation of Cell Culturing and Analysis
News Apr 29, 2009
Tecan and innovatis are working closely together under a new collaborative agreement to jointly market their robotic cell culture workstations and cell detection devices.
The collaboration concentrates on Cellavista, innovatis’ new automated image-based platform technology for cellular analysis, which has bright field and fluorescent capabilities and can process microplates, microscope slides and robot-friendly cell culture flasks.
Cellavista, in combination with Tecan’s flexible Freedom EVO® platform, allows automation of a wide range of cell-related processes including cell line development, cell proliferation, stem cell differentiation and various cell-based assays.
“We have already had a long, successful partnership with Tecan, and have worked very closely with Tecan application specialists on several customer projects,” said Michael Grohmann, Chief Executive Officer at innovatis. “Most Cellavista customers ask about full process automation and have shown great interest in Tecan’s automated solutions. They readily recognize the advantages of having a liquid handling and cell culture system that complements the detection capabilities of the Cellavista.”
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE